Milestone Biotechnologies

About Milestone Biotechnologies

Milestone Biotechnologies, established in 2014, operates as a high-tech enterprise focused on providing human and animal primary cell solutions to the pharmaceutical industry. The company functions as both a product supplier and a contract research organization (CRO), supporting clients such as pharmaceutical companies and research laboratories throughout various stages of drug development, from preclinical research to commercialization. The firm's business model is centered on offering specialized cell-related products and technical services, positioning itself as a one-stop provider for upstream cells and reagents in the cell therapy field.

The company was founded by Jinbao Zhang, who currently serves as CEO. Zhang has over two decades of experience in the life sciences sector, particularly in marketing, sales management, and formulating market access strategies. The management team also includes Dr. Huang Binlu as Chief Scientific Officer, who holds a Ph.D. in Cell Biology from Tsinghua University, and He Xiaoting as Chief Operating Officer, with a Master's degree in neurobiology from Fudan University. Since its inception, Milestone Biotechnologies has aimed to address the market's reliance on international suppliers by developing its own national brand of cell models under the trademark TPCS® (The Primary Cell Solution). The company launched its Shanghai R&D center in the same year it was founded and later established a significant R&D and production base in Zhejiang.

Milestone Biotechnologies' core offerings are organized around three main technology platforms: a cell separation service platform, a drug development platform, and a cell culture platform. Its services include the collection of human peripheral blood apheresis and the isolation and purification of a wide array of human and animal immune cells, such as PBMCs, T cells, B cells, NK cells, and CD34+ cells. The company also provides in-vitro hepatic modeling solutions, which encompass animal hepatocytes and non-parenchymal cells. Its product line features a variety of cell culture media and supplements designed for the optimal growth of primary cells, in addition to Kryogene™ Cell Freezing Media-CGT, a serum-free cryopreservation medium for cell and gene therapy applications. The company has successfully raised $13.6M in funding over two rounds from investors including Addor Capital and Industrial Securities.